In Landmark Phase III Head-to-Head Study- Prasugrel
Statistically Superior to Clopidogrel in Reducing Risk of Heart
Attack
<strong>Investigational compound reduces risk of majorcardiovascular events by 19 percent- significantly improves netclinical benefit despite increased bleeding</strong>